The evolution of aldosterone antagonists

被引:122
作者
Garthwaite, SM [1 ]
McMahon, EG [1 ]
机构
[1] Pfizer Inc, Global Project Managament, Skokie, IL USA
关键词
aldosterone; spironolactone; eplerenone; aldosterone blockers; aldosterone antagonists; selectivity;
D O I
10.1016/j.mce.2003.10.005
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Since the isolation and purification of aldosterone from adrenal extracts 50 years ago (Experientia 9 (1953) 33), scientists have learned a great deal about how and where aldosterone acts, the factors that control its release, what is its role in the pathophysiology of cardiovascular disease. how to make and study aldosterone antagonists, and for what medical purposes these agents are useful. In this paper, we will discuss the evolution of aldosterone antagonists from the relatively nonselective spironolactone (Aldactone(R)), to the highly selective eplerenone (Inspra(R)). Eplerenone represents a molecule with improved steroid receptor selectivity and pharmacokinetic properties ill man compared to spironolactone. Recent clinical results have demonstrated that these improvements translate into tolerability and efficacy in patients with cardiovascular disease. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:27 / 31
页数:5
相关论文
共 50 条
  • [21] The role of aldosterone antagonists in the management of resistant hypertension
    Mari K. Nishizaka
    David A. Calhoun
    Current Hypertension Reports, 2005, 7 : 343 - 347
  • [22] Aldosterone Receptor Antagonists Effective but Often Forgotten
    Maron, Bradley A.
    Leopold, Jane A.
    CIRCULATION, 2010, 121 (07) : 934 - 939
  • [23] The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure
    Hameedi A.
    Chadow H.L.
    Current Hypertension Reports, 2000, 2 (4) : 378 - 383
  • [24] Converging Indications of Aldosterone Antagonists (Spironolactone and Eplerenone): A Narrative Review of Safety Profiles
    Mohammed I Danjuma
    Ipshita Mukherjee
    Janine Makaronidis
    Serge Osula
    Current Hypertension Reports, 2014, 16
  • [25] Converging Indications of Aldosterone Antagonists (Spironolactone and Eplerenone): A Narrative Review of Safety Profiles
    Danjuma, Mohammed I.
    Mukherjee, Ipshita
    Makaronidis, Janine
    Osula, Serge
    CURRENT HYPERTENSION REPORTS, 2014, 16 (02)
  • [26] Rationale for the Use of Aldosterone Antagonists in Congestive Heart Failure
    Ricardo Rocha
    Gordon H. Williams
    Drugs, 2002, 62 : 723 - 731
  • [27] Mineralocorticoid Receptor Antagonists Cause Natriuresis in the Absence of Aldosterone
    Maeoka, Yujiro
    Su, Xiao-Tong
    Wang, Wen-Hui
    Duan, Xin-Peng
    Sharma, Avika
    Li, Na
    Staub, Olivier
    McCormick, James A.
    Ellison, David H.
    HYPERTENSION, 2022, 79 (07) : 1423 - 1434
  • [28] Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology
    Delyani, JA
    KIDNEY INTERNATIONAL, 2000, 57 (04) : 1408 - 1411
  • [29] Aldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease
    Bravo, EL
    CURRENT HYPERTENSION REPORTS, 2003, 5 (02) : 122 - 125
  • [30] The Effects of Aldosterone Antagonists in Patients With Resistant Hypertension: A Meta-Analysis of Randomized and Nonrandomized Studies
    Dahal, Khagendra
    Kunwar, Sumit
    Rijal, Jharendra
    Alqatahni, Fahad
    Panta, Raju
    Ishak, Noshi
    Russell, Roy Patterson
    AMERICAN JOURNAL OF HYPERTENSION, 2015, 28 (11) : 1376 - 1385